6533b7defe1ef96bd1275f3d
RESEARCH PRODUCT
SEOM clinical guideline for treatment of kidney cancer (2017)
Enrique GallardoM. J. Méndez-vidalJ. L. Pérez-graciaJ. M. Sepúlveda-sánchezM. CampayoI. Chirivella-gonzálezX. García-del-muroA. González-del-albaE. GrandeCristina SuárezUniversitat Autònoma De Barcelonasubject
OncologyCancer Researchmedicine.medical_specialtyCabozantinibhumanosRonyóClinical Guides in Oncologyurologic and male genital diseasesKidneylaw.inventionPazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRenal cell carcinomalawInternal medicinemedicineHumans030212 general & internal medicineCàncerCarcinoma Renal CellCancerMolecular pathologyAdjuvant treatment of cancerneoplasias renalesSystemic therapybusiness.industrySunitinibCarcinomaCorrectionKidney cancerGeneral Medicinemedicine.diseaseKidney NeoplasmsOncologychemistry030220 oncology & carcinogenesisLocalized diseaseNivolumabbusinessKidney cancermedicine.drugTractament adjuvant del càncerdescription
Abstract The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-11-01 |